Moving from “sick care” to true “health care”
Prevention and early detection are central to a migration from a “sick care” to a true “health care” system, and we are beginning to see meaningful evidence that digital technologies will be the enabler of that transformation. Digital signals from consumer-grade wearables are showing the promise to play an important role in the pandemic in helping individuals understand when they may be getting sick and when to seek further testing. The pandemic has accelerated this trend, but the momentum had been building, particularly in chronic conditions. A group of Danish researchers, publishing in the Journal of Medical Internet Research, identified that patients with chronic heart conditions who leveraged activity data from wearables for self-care, experienced the full spectrum of user experience, from motivation and reassurance to uncertainty and anxiety. A step beyond self-surveillance and self-care is “N-of-1 self-study” which is being explored in the Apollo Project, where a cohort of individuals are leveraging digital technology to better understand their difficult-to-diagnose or treat conditions. As person-generated health data become more ubiquitous, the latest analytical techniques will enable prediction and prevention of disease. A hint of the potential power of these analytical techniques is described in a recent paper by a group of scientists in Brazil and Germany who developed a computational model able to predict vital signs with greater than 80% accuracy, enabling treatment to be started in advance of the deterioration of patients’ health status.
We are excited about these market trends and believe they create an imperative for the Life Sciences industry to transform their businesses to be closer to the patient.
Digital Twins and the Emerging Science of Self: Implications for Digital Health Experience Design & “Small” Data | Frontiers in Digital Health
Patients Vastly Unaware of Insurers’ Access to Online Health Data | HealthITSecuity.com
Research: In collaboration with Omada Health, Evidation Health helped provide clinical validation on The Omada for Diabetes Program. The program achieved meaningful outcomes for participants just four months after beginning the program, including reduced A1c levels, significant cholesterol decrease for those with high cholesterol, increased medication adherence, and reduced diabetes stress. Read more about the results from this clinical study here.
Evidation was one of seven companies and academic institutions selected by the NIH from over 200 project proposals to develop digital health solutions that help address the COVID-19 pandemic. More details about the role of digital health technologies in the fight against the pandemic, and the specific contract awards can be found in the NIH announcement here.
Announcement: We are excited to announce that Evidation’s Board of Directors has appointed Christine Lemke as Co-CEO with Deborah Kilpatrick. See what both Deb and Christine have to say about their partnership as Co-CEOs here.
Point of View: Becoming more patient-centric begins with real world evidence. Learn more about how technology drives innovation, but research and trials must be accessible, privacy-safe and return value to participants to achieve patient engagement, featured in FiercePharma. Read the article here.